Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

Phase 2

Completed

Conditions: Atherosclerotic Cardiovascular Disease
Symptomatic Atherosclerosis
Type2 Diabetes
Familial Hypercholesterolemia

Interventions: Drug: Inclisiran
Drug: Evolocumab

First Posted Date: 2017-02-23

Last Posted Date: 2023-03-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 382

Registration Number: NCT03060577

Locations: 🇬🇧
Novartis Investigative Site, Worcester, United Kingdom

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Alpelisib
Drug: Fulvestrant
Drug: Letrozole
Drug: Goserelin
Drug: Leuprolide

First Posted Date: 2017-02-17

Last Posted Date: 2024-12-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 379

Registration Number: NCT03056755

Locations: 🇺🇸
Kaiser Permanente Medical Group, Anaheim, California, United States
🇺🇸
UCSF, San Francisco, California, United States
🇺🇸
University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States

and more 23 locations

Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients

Phase 4

Completed

Conditions: Plaque Psoriasis

Interventions: Biological: Placebo
Biological: Secukinumab

First Posted Date: 2017-02-16

Last Posted Date: 2023-03-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 102

Registration Number: NCT03055494

Locations: 🇺🇸
Novartis Investigative Site, Norfolk, Virginia, United States

Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment

Phase 3

Terminated

Conditions: Asthma

Interventions: Drug: QAW039 150 mg
Drug: QAW039 450 mg
Drug: Placebo

First Posted Date: 2017-02-14

Last Posted Date: 2020-10-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2538

Registration Number: NCT03052517

Locations: 🇬🇧
Novartis Investigative Site, Leicester, United Kingdom

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Phase 3

Terminated

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Drug: letrozole

First Posted Date: 2017-02-10

Last Posted Date: 2020-05-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT03050398

Locations: 🇺🇸
PeaceHealth St Joseph Medical Center, Bellingham, Washington, United States
🇺🇸
Arizona Oncology Associates PC HAL, Sedona, Arizona, United States
🇺🇸
Oncology Speciialists of Charlotte, Charlotte, North Carolina, United States

and more 3 locations

Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Fevipiprant

First Posted Date: 2017-02-09

Last Posted Date: 2020-12-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT03048448

Locations: 🇺🇸
Novartis Investigative Site, Orlando, Florida, United States

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Phase 2

Recruiting

Conditions: Advanced Solid Tumors Which Are cMET-dependent

Interventions: Drug: Capmatinib
Drug: Nazartinib
Drug: Gefitinib
Drug: Osimertinib

First Posted Date: 2017-02-02

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT03040973

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇪🇸
Novartis Investigative Site, Madrid, Spain

Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)

Phase 3

Completed

Conditions: Juvenile Psoriatic Arthritis
Enthesitis-related Arthritis

Interventions: Drug: secukinumab
Other: placebo

First Posted Date: 2017-01-26

Last Posted Date: 2022-08-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 86

Registration Number: NCT03031782

Locations: 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

Phase 2

Active, not recruiting

Conditions: Aplastic Anemia

Interventions: Drug: Eltrombopag
Drug: hATG
Drug: CsA

First Posted Date: 2017-01-19

Last Posted Date: 2024-12-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 51

Registration Number: NCT03025698

Locations: 🇺🇸
Aflac Cancerand Blood Disorders Ctr, Atlanta, Georgia, United States
🇺🇸
Ann and Robert H Lurie Childrens Hospital of Chicago SC, Chicago, Illinois, United States
🇺🇸
Cleveland Clinic Foundation Cleveland Clinic 5, Cleveland, Ohio, United States

and more 10 locations

Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis

Phase 4

Terminated

Conditions: Plaque Psoriasis

Interventions: Radiation: nb-UVB
Biological: Secukinumab

First Posted Date: 2017-01-13

Last Posted Date: 2024-09-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 196

Registration Number: NCT03020199

Locations: 🇬🇧
Novartis Investigative Site, Salford, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy